J D Kent
Overview
Explore the profile of J D Kent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lichtiger S, Binion D, Wolf D, Present D, Bensimon A, Wu E, et al.
Aliment Pharmacol Ther
. 2010 Oct;
32(10):1228-39.
PMID: 20955442
Background: Adalimumab induces and maintains remission in adults with Crohn's disease. Aim: To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including...
2.
Colombel J, Schwartz D, Sandborn W, Kamm M, DHaens G, Rutgeerts P, et al.
Gut
. 2009 Feb;
58(7):940-8.
PMID: 19201775
Objective: To evaluate the efficacy of adalimumab in the healing of draining fistulas in patients with active Crohn's disease (CD). Design: A phase III, multicentre, randomised, double-blind, placebo controlled study...
3.
Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D, et al.
Gut
. 2007 Feb;
56(9):1232-9.
PMID: 17299059
Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety of adalimumab maintenance...
4.
Schiff M, Burmester G, Kent J, Pangan A, Kupper H, Fitzpatrick S, et al.
Ann Rheum Dis
. 2006 Jan;
65(7):889-94.
PMID: 16439435
Objective: To assess the safety of adalimumab in global clinical trials and postmarketing surveillance among patients with rheumatoid arthritis (RA). Methods: Safety data for adalimumab treated patients from randomised controlled...
5.
Goldstein J, Eisen G, Agrawal N, Stenson W, Kent J, Verburg K
Aliment Pharmacol Ther
. 2004 Sep;
20(5):527-38.
PMID: 15339324
Aim: In a predefined analysis, data were pooled from eight blinded, randomized, controlled trials, and separately from three long-term, open-label trials to determine the rate of upper gastrointestinal ulcer complications...
6.
Goldstein J, Kivitz A, Verburg K, Recker D, Palmer R, Kent J
Aliment Pharmacol Ther
. 2003 Jul;
18(1):125-32.
PMID: 12848634
Background: In long-term outcomes studies, cyclooxygenase COX-2 specific inhibitors spare COX-1 at supratherapeutic doses and therefore demonstrate improved gastrointestinal safety over nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs). However, in clinical practice,...
7.
Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, WHELTON A, et al.
JAMA
. 2000 Sep;
284(10):1247-55.
PMID: 10979111
Context: Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1. Whether COX-2-specific inhibitors are associated with...
8.
Kojda G, Laursen J, Ramasamy S, Kent J, Kurz S, Burchfield J, et al.
Cardiovasc Res
. 1999 Aug;
42(1):206-13.
PMID: 10435012
Objective: Both disruption of the endothelial nitric oxide synthase (eNOS) gene and pharmacological inhibition of the NOS produce modest hypertension. It is unclear if and to what extent NOS isoforms...
9.
Vejlstrup N, Bouloumie A, Boesgaard S, Andersen C, Nielsen-Kudsk J, Mortensen S, et al.
J Mol Cell Cardiol
. 1998 Aug;
30(6):1215-23.
PMID: 9689595
The inducible nitric oxide (NO) synthase (iNOS or NOS2) generates a prolonged release of large amounts of NO which may be cytotoxic and/or inhibit myocyte contractility. It has been suggested...
10.
Kent J, Sergeant S, Burns D, McPhail L
J Immunol
. 1996 Nov;
157(10):4641-7.
PMID: 8906844
The intracellular mechanisms that regulate the function of human neutrophils are not well understood. Receptor-initiated signaling events result in the production of several second messengers (e.g., Ca2+, diacylglycerol, phosphatidic acid,...